Aptahem enters new consortium financed by the KK Foundation
Aptahem (publ) today announce that the company enters a consortium together with Örebro University, Attgeno AB, BioReperia AB, Buzzard Pharmaceuticals AB, Lipum AB, Thermo Fisher Scientific och Toleranzia AB. The newly established consortium aims to evaluate new treatments to reduce inflammation in cardiovascular diseases and breast cancer.
The joint research project, titled Drug discovery targeting inflammation – novel therapeutic aspects on vascular inflammation, thrombosis and breast cancer, has obtained financing from the Swedish KK-foundation and will run over a four-year period with start in late 2022. Aptahem will primarily provide the project with its drug candidate Apta-1 and contribute with expertise competence with Dr. Luiza Jedlina as scientific advisor on aptamer-based therapies and specifically of Apta-1’s inhibition of inflammation and thrombosis.
Aptahem’s CEO Mikael Lindstam was part of the steering committee representing the consortium’s application to the KK Foundation, and was invited to describe the project and answer questions from the KK Foundation before they granted the application.
CEO Mikael Lindstam comments:
”It is great news to once again be trusted to be part of a consortium financed by the KK Foundation. For the past two years our collaboration with the research group at Örebro University, headed by Professor Magnus Grenegård, has been very fruitful and resulted in ground-breaking knowledge about our drug candidate Apta-1. We are now looking forward to continuing building the fruitful collaboration with the group in Örebro and together develop treatments for serious diseases caused by inflammation.”
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.